Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies

Bibliography

• Wimo A, Jonsson L, Bond J, et al. The worldwide economic impact of dementia 2010. Alzheimers Dement 2013;9(1):1-11. e3
   PubMed Web of Science ®Google Scholar
• Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10(9):698-712
   PubMed Web of Science ®Google Scholar
• Jones EL, Hanney M, Francis PT, et al. Amyloid beta concentrations in older people with Down syndrome and dementia. Neurosci Lett 2009;451(2):162-4
   PubMedGoogle Scholar
• Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature 2012;488(7409):96-9
   PubMed Web of Science ®Google Scholar
• Ballard C, Gauthier S, Corbett A, et al. Alzheimer’s disease. Lancet 2011;377(9770):1019-31
   PubMed Web of Science ®Google Scholar
• McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65(12):1863-72
   PubMed Web of Science ®Google Scholar
• Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24(2):197-211
   PubMed Web of Science ®Google Scholar
• Lippa CF. Synaptophysin immunoreactivity in Pick’s disease: comparison with Alzheimer’s disease and dementia with Lewy bodies. Am J Alzheimers Dis Other Demen 2004;19(6):341-4
   PubMedGoogle Scholar
• Wakabayashi K, Tanji K, Odagiri S, et al. The Lewy body in Parkinson’s disease and related neurodegenerative disorders. Mol Neurobiol 2013;47(2):495-508
   PubMed Web of Science ®Google Scholar
• Jellinger KA, Wenning GK, Seppi K. Predictors of survival in dementia with lewy bodies and Parkinson dementia. Neurodegener Dis 2007;4(6):428-30
   PubMedGoogle Scholar
• Aarsland D, Ballard C, Rongve A, et al. Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia. Curr Neurol Neurosci Rep 2012;12(5):492-501
   PubMed Web of Science ®Google Scholar
• Ballard C, Corbett A, Sharp S. Aligning the evidence with practice: NICE guidelines for drug treatment of Alzheimer’s disease. Expert Rev Neurother 2011;11(3):327-9
   PubMed Web of Science ®Google Scholar
• Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease. Cochrane Database Syst Rev 2012;3:CD006504
   PubMed Web of Science ®Google Scholar
• Goldman JG, Goetz CG, Brandabur M, et al. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord 2008;23(15):2248-50
   PubMedGoogle Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):311-21
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370(4):322-33
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61(1):46-54
   PubMed Web of Science ®Google Scholar
• Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6(2):144-51
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372(9634):216-23
   PubMed Web of Science ®Google Scholar
• Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011;31(25):9323-31
   PubMed Web of Science ®Google Scholar
• Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012;11(7):597-604
   PubMed Web of Science ®Google Scholar
• Ryan JM, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer’s disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis 2009;17(2):243
   PubMed Web of Science ®Google Scholar
• Bard F, Fox M, Friedrich S, et al. Sustained levels of antibodies against Abeta in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. Exp Neurol 2012;238(1):38-43
   PubMedGoogle Scholar
• Chiang K, Koo EH. Emerging therapeutics for Alzheimer’s disease. Annu Rev Pharmacol Toxicol 2014;54:381-405
   PubMed Web of Science ®Google Scholar
• Coric V, van Dyck CH, Salloway S, et al. Safety and tolerability of the gamma-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease. Arch Neurol 2012;69(11):1430-40
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65(8):1031-8
   PubMedGoogle Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013;369(4):341-50
   PubMed Web of Science ®Google Scholar
• Gupta VB, Gupta VK, Martins R. Semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013;369(17):1660-1
   PubMedGoogle Scholar
• Forman M, Palcza J, Tseng J, et al. The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid Aβ peptides in healthy subjects following single- and multiple-dose administration. Alzheimers Dementia 2012;8(4 Suppl):P704
   Google Scholar
• Cai J, Qi X, Kociok N, et al. Beta-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med 2012;4(9):980-91
   PubMed Web of Science ®Google Scholar
• Kim DY, Gersbacher MT, Inquimbert P, et al. Reduced sodium channel Na(v)1.1 levels in BACE1-null mice. J Biol Chem 2011;286(10):8106-16
   PubMedGoogle Scholar
• Kobayashi D, Zeller M, Cole T, et al. BACE1 gene deletion: impact on behavioral function in a model of Alzheimer’s disease. Neurobiol Aging 2008;29(6):861-73
   PubMed Web of Science ®Google Scholar
• Wischik CM, Harrington CR, Storey JM. Tau-aggregation inhibitor therapy for Alzheimer’s disease. Biochem Pharmacol 2014;88(4):529-39
   PubMed Web of Science ®Google Scholar
• Rojas JC, Bruchey AK, Gonzalez-Lima F. Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 2012;96(1):32-45
   PubMedGoogle Scholar
• Stack C, Jainuddin S, Elipenahli C, et al. Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet 2014; Epub ahead of print
   PubMedGoogle Scholar
• Wischik CM, Bentham P, Wischik DJ, et al. Tau aggregation inhibitor (TAI) therapy with rember™ arrests disease progression in mild and moderate Alzheimer’s disease over 50 weeks. Alzheimers Dement 2008;4(4):T167
   PubMed Web of Science ®Google Scholar
• Spires-Jones TL, Friedman T, Pitstick R, et al. Methylene blue does not reverse existing neurofibrillary tangle pathology in the rTg4510 mouse model of tauopathy. Neurosci Lett 2014;562(0):63-8
   PubMedGoogle Scholar
• Tariot PN, Schneider LS, Cummings J, et al. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry 2011;68(8):853-61
   PubMed Web of Science ®Google Scholar
• Zhang X, Heng X, Li T, et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer’s disease transgenic mouse model. J Alzheimers Dis 2011;24(4):739-49
   PubMedGoogle Scholar
• Straten G, Saur R, Laske C, et al. Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer’s disease. Curr Alzheimer Res 2011;8(8):853-9
   PubMed Web of Science ®Google Scholar
• Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer’s disease. Curr Alzheimer Res 2013;10(1):104-7
   PubMedGoogle Scholar
• Marcade M, Bourdin J, Loiseau N, et al. Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J Neurochem 2008;106(1):392-404
   PubMed Web of Science ®Google Scholar
• Vellas B, Sol O, Snyder PJ, et al. EHT0202 in Alzheimer’s disease: a 3-month, randomized, placebo-controlled, double-blind study. Curr Alzheimer Res 2011;8(2):203-12
   PubMed Web of Science ®Google Scholar
• Squitti R, Simonelli I, Ventriglia M, et al. Meta-analysis of serum non-ceruloplasmin copper in Alzheimer’s disease. J Alzheimers Dis 2014;38(4):809-22
   PubMedGoogle Scholar
• Jenagaratnam L, McShane R. Clioquinol for the treatment of Alzheimer’s disease. Cochrane Database Syst Rev 2006(1):CD005380
   PubMedGoogle Scholar
• Ma T, Trinh MA, Wexler AJ, et al. Suppression of eIF2alpha kinases alleviates Alzheimer’s disease-related plasticity and memory deficits. Nat Neurosci 2013;16(9):1299-305
   PubMed Web of Science ®Google Scholar
• Corbett A, Pickett J, Burns A, et al. Drug repositioning for Alzheimer’s disease. Nat Rev Drug Discov 2012;11(11):833-46
   PubMed Web of Science ®Google Scholar
• Bassil F, Fernagut PO, Bezard E, et al. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification? Prog Neurobiol 2014;118C:1-18
   Google Scholar
• Reger MA, Watson GS, Green PS, et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008;70(6):440-8
   PubMed Web of Science ®Google Scholar
• Craft S, Baker LD, Montine TJ, et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012;69(1):29-38
   PubMed Web of Science ®Google Scholar
• McClean PL, Gault VA, Harriott P, et al. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer’s disease. Eur J Pharmacol 2010;630(1-3):158-62
   PubMed Web of Science ®Google Scholar
• Bomfim TR, Forny-Germano L, Sathler LB, et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest 2012;122(4):1339-53
   PubMed Web of Science ®Google Scholar
• Corbett A, Ballard C. Is a potential Alzheimer’s therapy already in use for other conditions? Can medications for hypertension, diabetes and acne help with the symptoms? Expert Opin Investig Drugs 2013;22(8):941-3
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Egashira N, Takagaki Y, et al. Nilvadipine prevents the impairment of spatial memory induced by cerebral ischemia combined with beta-amyloid in rats. Biol Pharm Bull 2007;30(4):698-701
   PubMed Web of Science ®Google Scholar
• Kennelly SP, Abdullah L, Paris D, et al. Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. Int J Geriatr Psychiatry 2011;26(10):1038-45
   PubMedGoogle Scholar
• Kennelly S, Abdullah L, Kenny RA, et al. Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer’s patients – an open-label trial. Int J Geriatr Psychiatry 2012;27(4):415-22
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162(18):2046-52
   PubMed Web of Science ®Google Scholar
• Forloni G, Colombo L, Girola L, et al. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 2001;487(3):404-7
   PubMed Web of Science ®Google Scholar
• Parachikova A, Vasilevko V, Cribbs DH, et al. Reductions in Amyloid-beta-Derived Neuroinflammation, with Minocycline, Restore Cognition but do not Significantly Affect Tau Hyperphosphorylation. J Alzheimers Dis 2010;21(2):527-42
   PubMed Web of Science ®Google Scholar
• Cuello AC, Ferretti MT, Leon WC, et al. Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. Neurodegener Dis 2010;7(1-3):96-8
   PubMed Web of Science ®Google Scholar
• Ding Y, Qiao AM, Wang ZQ, et al. Retinoic Acid Attenuates beta-Amyloid Deposition and Rescues Memory Deficits in an Alzheimer’s Disease Transgenic Mouse Model. J Neurosci 2008;28(45):11622-34
   PubMed Web of Science ®Google Scholar
• Jarvis CI, Goncalves MB, Clarke E, et al. Retinoic acid receptor-alpha signalling antagonizes both intracellular and extracellular amyloid-beta production and prevents neuronal cell death caused by amyloid-beta. Eur J Neurosci 2010;32(8):1246-55
   PubMedGoogle Scholar
• Wright JW, Harding JW. Brain renin-angiotensin-A new look at an old system. Prog Neurobiol 2011;95(1):49-67
   PubMed Web of Science ®Google Scholar
• Li N-C, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. Br Med J 2010;340:b5465
   PubMed Web of Science ®Google Scholar
• Davies N, Kehoe P, Ben-Shlomo Y, et al. Associations of angiotensin-II receptor blockers and ace inhibitors with Alzheimer’s disease: a nested case-control study within the UK General Practice Research Database. J Epidemiol Commun Health 2011;65:A45-A
   Google Scholar
• Anderson C, Teo K, Gao P, et al. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol 2011;10(1):43-53
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, et al. The Study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21(5):875-86
   PubMed Web of Science ®Google Scholar
• Skoog I, Lithell H, Hansson L, et al. Effect of baseline cognitive function and anti hypertensive treatment on cognitive and cardiovascular outcomes: study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005;18(8):1052-9
   PubMed Web of Science ®Google Scholar
• O’Caoimh R, Healy L, Gao Y, et al. Effects of Centrally acting angiotensin converting enzyme inhibitors on functional decline in patients with Alzheimer’s disease. J Alzheimers Dis 2014;40(3):595-603
   PubMedGoogle Scholar
• Piette F, Belmin J, Vincent H, et al. Masitinib as an adjunct therapy for mild-to-moderate Alzheimer’s disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther 2011;3(2):16
   PubMed Web of Science ®Google Scholar
• Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289(21):2819-26
   PubMed Web of Science ®Google Scholar
• Green RC, Schneider LS, Amato DA, et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 2009;302(23):2557-64
   PubMed Web of Science ®Google Scholar
• Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 2004;62(1):66-71
   PubMed Web of Science ®Google Scholar
• Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993;43(8):1609-11
   PubMed Web of Science ®Google Scholar
• Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer’s disease patients. Cochrane Database Syst Rev 2002(2):CD003673
   PubMedGoogle Scholar
• de Jong D, Jansen R, Hoefnagels W, et al. No effect of one-year treatment with indomethacin on Alzheimer’s disease progression: a randomized controlled trial. PLoS One 2008;3(1):e1475
   PubMed Web of Science ®Google Scholar
• Corbett A, Ballard C. New and emerging treatments for Alzheimer’s disease. Expert Opin Emerg Drugs 2012;17(2):147-56
   PubMed Web of Science ®Google Scholar
• Shi JQ, Shen W, Chen J, et al. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 2011;1368:239-47
   PubMed Web of Science ®Google Scholar
• Corbett A, Ballard C. The value of vitamin E as a treatment for Alzheimer’s disease remains unproven despite functional improvement, due to a lack of established effect on cognition or other outcomes from RCTs. Evid Based Med 2014; Epub ahead of print
   PubMedGoogle Scholar
• Remington R, Chan A, Paskavitz J, et al. Efficacy of a vitamin/nutriceutical formulation for moderate-stage to later-stage Alzheimer’s disease: a placebo-controlled pilot study. Am J Alzheimers Dis Other Demen 2009;24(1):27-33
   PubMed Web of Science ®Google Scholar
• Tong XK, Nicolakakis N, Fernandes P, et al. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol Dis 2009;35(3):406-14
   PubMedGoogle Scholar
• Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010;74(12):956-64
   PubMed Web of Science ®Google Scholar
• Geldenhuys WJ, Van der Schyf CJ. The serotonin 5-HT6 receptor: a viable drug target for treating cognitive deficits in Alzheimer’s disease. Expert Rev Neurother 2009;9(7):1073-85
   PubMed Web of Science ®Google Scholar
• Arnt J, Bang-Andersen B, Grayson B, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 2010;13(8):1021-33
   PubMed Web of Science ®Google Scholar
• Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry 2011;26(5):536-44
   PubMed Web of Science ®Google Scholar
• Preskorn SH, Gawryl M, Dgetluck N, et al. Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract 2014;20(1):12-24
   PubMed Web of Science ®Google Scholar
• Prickaerts J, van Goethem NP, Chesworth R, et al. EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors. Neuropharmacology 2012;62(2):1099-110
   PubMed Web of Science ®Google Scholar
• Foster DJ, Choi DL, Conn PJ, et al. Activation of M and M muscarinic receptors as potential treatments for Alzheimer’s disease and schizophrenia. Neuropsychiatr Dis Treat 2014;10:183-91
   PubMed Web of Science ®Google Scholar
• Ballard C, Kahn Z, Corbett A. Treatment of dementia with Lewy bodies and Parkinson’s disease dementia. Drugs Aging 2011;28(10):769-77
   PubMed Web of Science ®Google Scholar
• van Laar T, De Deyn PP, Aarsland D, et al. Effects of cholinesterase inhibitors in Parkinson’s disease dementia: a review of clinical data. CNS Neurosci Ther 2011;17(5):428-41
   PubMed Web of Science ®Google Scholar
• Mori E, Ikeda M, Kosaka K. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol 2012;72(1):41-52
   PubMed Web of Science ®Google Scholar
• Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009;8(7):613-18
   PubMed Web of Science ®Google Scholar
• Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010;9(10):969-77
   PubMed Web of Science ®Google Scholar
• Marsh L, Biglan K, Gerstenhaber M, et al. Atomoxetine for the treatment of executive dysfunction in Parkinson’s disease: a pilot open-label study. Mov Disord 2009;24(2):277-82
   PubMed Web of Science ®Google Scholar
• Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75(5):448-55
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23
   PubMed Web of Science ®Google Scholar
• Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011;26(10):1851-8
   PubMed Web of Science ®Google Scholar
• Ballard CG, Chalmers KA, Todd C, et al. Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies. Neurology 2007;68(20):1726-9
   PubMedGoogle Scholar
• Mangialasche F, Solomon A, Winblad B, et al. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol 2010;9(7):702-16
   PubMed Web of Science ®Google Scholar